Genetic Counselling, Testing, and Management of Hereditary Breast and Ovarian Cancer Syndrome in India: Updated Expert Consensus Recommendations from Indian Society of Medical and Pediatric Oncology

Abstract

Introduction Hereditary breast and ovarian cancer (HBOC) is driven by mutations in BRCA1/2 and related genes. Their understanding is vital to appropriate management of such patients and at-risk families, including counselling and genetic testing. Several important recent advances have made it necessary to revise the previous recommendations we made for India in 2020.

Materials and Methods This consensus document was developed with the authors as key experts in the field. Published evidence, real-world data, and expert interpretation were used by a modified Delphi method to finalize these recommendations.

Results Detailed description and process for identifying patients at risk, doing their counselling, selecting the right molecular test, interpreting the results, and determining the optimal mode of action to attenuate risk of HOBC or its recurrence have been provided in a clear and lucid manner. Differences between germline and somatic mutations are described. Information from publicly available databases was used to fine-tune the guidelines—as more information had becomes available since the time of writing the first guidelines. Risk of various cancer types and corresponding risk reduction strategies have been explained.

Conclusion Community oncologists in India, SAARC region, and other low- and middle-income countries should use these guidelines in their clinical practice to optimize genetic counselling, molecular testing, and management of patients with HBOC.

Keywords

hereditary cancer - therapy - driver mutations - guidelines

Patient Consent

Patient consent not required.

Publication History

Article published online:
03 March 2025

• References

• 1 Bhardwaj PV, Dulala R, Rajappa S, Loke C. Breast cancer in India: screening, detection, and management. Hematol Oncol Clin North Am 2024; 38 (01) 123-135
• 2 Mohanty SK, Wadasadawala T, Sen S, Khan PK. Socio-economic variations of breast cancer treatment and discontinuation: a study from a public tertiary cancer hospital in Mumbai, India. BMC Womens Health 2023; 23 (01) 113
• 3 Waghela BN, Pandit RJ, Puvar A. et al. Identification of novel exonic variants contributing to hereditary breast and ovarian cancer in west Indian population. Gene 2023; 852: 147070
• 4 American College of Obstetricians and Gynecologists. ACOG Committee on Practice Bulletins—Gynecology, ACOG Committee on Genetics. et al. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009; 113: 957-966 PubMed
• 5 Honrado E, Benítez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 2005; 18 (10) 1305-1320
• 6 Ford D, Easton DF, Stratton M. et al; The Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62 (03) 676-689
• 7 Gorodetska I, Kozeretska I, Dubrovska A. BRCA genes: the role in genome stability, cancer stemness and therapy resistance. J Cancer 2019; 10 (09) 2109-2127
• 8 Struewing JP, Hartge P, Wacholder S. et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336 (20) 1401-1408
• 9 Sarin R. A decade of discovery of BRCA1 and BRCA2: are we turning the tide against hereditary breast cancers?. J Cancer Res Ther 2006; 2 (04) 157-158
• 10 Joshi S, Murali-Nanavati S, Shylasree TS. et al. Synchronous and metachronous breast and ovarian cancers: experience from a single tertiary care cancer centre in India. Indian J Surg Oncol 2023; 14 (04) 809-821
• 11 Marsh D, Zori R. Genetic insights into familial cancers– update and recent discoveries. Cancer Lett 2002; 181 (02) 125-164
• 12 Rhiem K, Schmutzler R. Impact of prophylactic mastectomy in BRCA1/2 mutation carriers. Breast Care (Basel) 2014; 9 (06) 385-389
• 13 Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994; 73 (03) 643-651
• 14 Krivokuca A, Mihajlovic M, Susnjar S. et al. Mutational profile of hereditary breast and ovarian cancer - establishing genetic testing guidelines in a developing country. Curr Probl Cancer 2022; 46 (01) 100767
• 15 Peto J, Collins N, Barfoot R. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999; 91 (11) 943-949
• 16 Rajagopal T, Seshachalam A, Jothi A. et al. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India. Mol Biol Rep 2022; 49 (04) 3025-3032
• 17 Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res 2019; 11: 2321-2337
• 18 Kang PC, Phuah SY, Sivanandan K. et al. Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history. Breast Cancer Res Treat 144: 635-642 2014;
• 19 Malhotra H, Kowtal P, Mehra N. et al. Genetic counseling, testing, and management of HBOC in India: an expert consensus document from Indian Society of Medical and Pediatric Oncology. JCO Glob Oncol 2020; 6: 991-1008
• 20 Parikh PM, Aggarwal S, Biswas G. et al. Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. South Asian J Cancer 2023; 12 (02) 93-99
• 21 Phadke SR, Pandey A, Puri RD, Patil SJ. Genetic counseling: the impact in Indian milieu. Indian J Pediatr 2004; 71 (12) 1079-1082
• 22 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment—Breast, Ovarian, and pancreatic (version 1.2020). Accessed July 11, 2024 at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
• 23 Riley BD, Culver JO, Skrzynia C. et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2012; 21 (02) 151-161
• 24 Allen CG, Roberts M, Guan Y. Exploring predictors of genetic counseling and testing for hereditary breast and ovarian cancer: findings from the 2015 U.S. National Health Interview Survey. J Pers Med 2019; 9 (02) 26
• 25 Fallowfield L, Jenkins V. Effective communication skills are the key to good cancer care. Eur J Cancer 1999; 35 (11) 1592-1597
• 26 Robson ME, Bradbury AR, Arun B. et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2015; 33 (31) 3660-3667
• 27 National Pathology Accreditation Advisory Council. Classification of Human Genetic Testing. Canberra, ACT, Australia, Laboratory Accreditation Standards and Guidelines for Nucleic Acid Detection and Analysis; 2007
• 28 Rantanen E, Hietala M, Kristoffersson U. et al. Regulations and practices of genetic counselling in 38 European countries: the perspective of national representatives. Eur J Hum Genet 2008; 16 (10) 1208-1216
• 29 Darooei M, Poornima S, Salma BU. et al. Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population. Tumour Biol 2017; 39 (02) 1010428317694303
• 30 Rich EC, Burke W, Heaton CJ. et al. Reconsidering the family history in primary care. J Gen Intern Med 2004; 19 (03) 273-280
• 31 Yip CH, Evans DG, Agarwal G. et al. Global disparities in breast cancer genetics testing, counselling and management. World J Surg 2019; 43 (05) 1264-1270
• 32 Wood ME, Kadlubek P, Pham TH. et al. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol 2014; 32 (08) 824-829
• 33 Brédart A, Kop JL, De Pauw A. et al. Effect on perceived control and psychological distress of genetic knowledge in women with breast cancer receiving a BRCA1/2 test result. Breast 2017; 31: 121-127
• 34 Mancini J, Noguès C, Adenis C. et al. Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing. Eur J Cancer 2006; 42 (07) 871-881
• 35 Quinn VF, Meiser B, Kirk J. et al. Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial. Genet Med 2017; 19 (04) 448-456
• 36 Randall J, Butow P, Kirk J, Tucker K. Psychological impact of genetic counselling and testing in women previously diagnosed with breast cancer. Intern Med J 2001; 31 (07) 397-405
• 37 National Cancer Institute. Susceptibility genes. Accessed July 11, 2024 at: https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq
• 38 Kowalewski A, Szylberg Ł, Saganek M, Napiontek W, Antosik P, Grzanka D. Emerging strategies in BRCA-positive pancreatic cancer. J Cancer Res Clin Oncol 2018; 144 (08) 1503-1507
• 39 Singh J, Thota N, Singh S. et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations. Breast Cancer Res Treat 2018; 170 (01) 189-196
• 40 Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007; 31 (05) 1031-1040
• 41 Sharma-Oates A, Shaaban AM, Tomlinson I, Wynne L, Cazier JB, Sundar S. Heterogeneity of germline variants in high risk breast and ovarian cancer susceptibility genes in India. Precis Clin Med 2018; 1 (02) 75-87
• 42 Thirthagiri E, Lee SY, Kang P. et al. Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 2008; 10 (04) R59
• 43 Gupta S, Rajappa S, Advani S. et al. Prevalence of BRCA1 and BRCA2 mutations among patients with ovarian, primary peritoneal, and fallopian tube cancer in India: a multicenter cross-sectional study. JCO Glob Oncol 2021; 7: 849-861
• 44 Mittal A, Deo SVS, Gogia A. et al. Profile of pathogenic mutations and evaluation of germline genetic testing criteria in consecutive breast cancer patients treated at a North Indian tertiary care center. Ann Surg Oncol 2022; 29 (02) 1423-1432
• 45 Pramanik R, Upadhyay A, Khurana S. et al. Comprehensive germline genomic profiling of patients with ovarian cancer: a cross-sectional study. Indian J Med Paediatr Oncol 2022; 43 (04) 361-368
• 46 Kadri MSN, Patel KM, Bhargava PA. et al. Mutational landscape for Indian hereditary breast and ovarian cancer cohort suggests need for identifying population specific genes and biomarkers for screening. Front Oncol 2021; 10: 568786
• 47 Chheda P, Pande S, Dama T. et al. Spectrum of germline BRCA mutations in hereditary breast and ovarian cancer syndrome in Indian population: A central reference laboratory experience. Cancer Res Stat Treat 2020; 3: 32-41
• 48 Mehta A, Vasudevan S, Sharma SK. et al. Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India. Cancer Manag Res 2018; 10: 6505-6516
• 49 Suryavanshi M, Kumar D, Panigrahi MK, Chowdhary M, Mehta A. Detection of false positive mutations in BRCA gene by next generation sequencing. Fam Cancer 2017; 16 (03) 311-317
• 50 Stewart MD, Merino Vega D, Arend RC. et al. Homologous recombination deficiency: concepts, definitions, and assays. Oncologist 2022; 27 (03) 167-174
• 51 Bekos C, Grimm C, Kranawetter M. et al. Reliability of tumor testing compared to germline testing for detecting BRCA1 and BRCA2 mutations in patients with epithelial ovarian cancer. J Pers Med 2021; 11 (07) 593
• 52 Chandrsekaran D, Sobocan M, Blyuss O. et al. Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study. Cancers (Basel) 2021; 13: 4344
• 53 Miller RE, Leary A, Scott CL. et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol 2020; 31 (12) 1606-1622
• 54 Owens DK, Davidson KW, Krist AH. et al; US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA 2019; 322 (07) 652-665
• 55 Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation. J Biosci 2009; 34 (03) 415-422
• 56 McAlarnen L, Stearns K, Uyar D. Challenges of genomic testing for hereditary breast and ovarian cancers. Appl Clin Genet 2021; 14: 1-9
• 57 Price KS, Svenson A, King E, Ready K, Lazarin GA. Inherited cancer in the age of next-generation sequencing. Biol Res Nurs 2018; 20 (02) 192-204
• 58 Ruiz de Garibay G, Gutiérrez-Enríquez S, Garre P. et al. Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their origin. Breast Cancer Res Treat 2012; 133 (01) 273-283
• 59 Reddy RRS, Ramanujam MV. High throughput sequencing-based approaches for gene expression analysis. Methods Mol Biol 2018; 1783: 299-323
• 60 Avoiding the common mistakes labs make when launching hereditary cancer panel tests Jeanette McCarthy. Accessed July 11, 2024 at: www.fabricgenomics.com
• 61 Feliubadaló L, Lopez-Doriga A, Castellsagué E. et al. Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. Eur J Hum Genet 2013; 21 (08) 864-870
• 62 Tucker K. Germline genetic testing: why it matters and where we are failing. Gynaecologic Oncology Consult 2022 . Accessed November 13, 2023 at: https://www.mdedge.com/obgyn/article/258782/gynecologic-cancer/germline-genetic-testing-why-it-matters-and-where-we-are
• 63 Carvalho CM, Braga LDC, Silva LM, Chami AM, Silva Filho ALD. Germline mutations landscape in a cohort of the state of Minas Gerais, Brazil, in patients who underwent genetic counseling for gynecological and breast cancer. Rev Bras Ginecol Obstet 2023; 45 (02) 74-81
• 64 Wallace AJ. New challenges for BRCA testing: a view from the diagnostic laboratory. Eur J Hum Genet 2016; 24 (Suppl. 01) S10-S18
• 65 Jennings LJ, Arcila ME, Corless C. et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn 2017; 19 (03) 341-365
• 66 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
• 67 Roy S, Coldren C, Karunamurthy A. et al. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists. J Mol Diagn 2018; 20 (01) 4-27
• 68 Do H, Wong SQ, Li J, Dobrovic A. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clin Chem 2013; 59 (09) 1376-1383
• 69 Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for homologous recombination deficiency in cancer. J Natl Cancer Inst 2018; 110 (07) 704-713
• 70 Plon SE, Eccles DM, Easton D. et al; IARC Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008; 29 (11) 1282-1291
• 71 Meijers-Heijboer H, van Geel B, van Putten WL. et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345 (03) 159-164
• 72 Domchek SM, Friebel TM, Singer CF. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304 (09) 967-975
• 73 Kauff ND, Satagopan JM, Robson ME. et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346 (21) 1609-1615
• 74 Zuntini R, Ferrari S, Bonora E. et al. Dealing with BRCA1/2 unclassified variants in a cancer genetics clinic: does cosegregation analysis help?. Front Genet 2018; 9: 378
• 75 Neff RT, Senter L, Salani R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol 2017; 9 (08) 519-531
• 76 Nagahashi M, Shimada Y, Ichikawa H. et al. Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing. J Surg Res 2017; 220: 125-132
• 77 Cazzato G, Caporusso C, Arezzo F. et al. Formalin-fixed and paraffin-embedded samples for next generation sequencing: problems and solutions. Genes (Basel) 2021; 12 (10) 1472
• 78 Moore DA, Balbi K, Ingham A, Arkenau HT, Bennett P. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice. J Clin Pathol 2018; 71 (11) 1001-1006
• 79 Rajkumar T, Meenakumari B, Mani S, Sridevi V, Sundersingh S. Targeted resequencing of 30 genes improves the detection of deleterious mutations in South Indian women with breast and/or ovarian cancers. Asian Pac J Cancer Prev 2015; 16 (13) 5211-5217
• 80 Borg A, Haile RW, Malone KE. et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat 2010; 31 (03) E1200-E1240
• 81 Exchange BRCA. . Summary view. Accessed July 11, 2024 at: https://brcaexchange.org/
• 82 Lindor NM, Goldgar DE, Tavtigian SV, Plon SE, Couch FJ. BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. Oncologist 2013; 18 (05) 518-524
• 83 Ledermann J, Harter P, Gourley C. Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2015; 16 (04) e158
• 84 Hennessy BT, Timms KM, Carey MS. et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010; 28 (22) 3570-3576
• 85 Ledermann J, Harter P, Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15 (08) 852-861
• 86 Sandhu SK, Schelman WR, Wilding G. et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013; 14 (09) 882-892
• 87 Agarwal A, Baghmar S, Dodagoudar C. et al. PARP inhibitor in platinum-resistant ovarian cancer: single-center real-world experience. JCO Glob Oncol 2021; 7: 506-511
• 88 Vergote I, Ray-Coquard I, Anderson DM. et al. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer 2021; 157: 415-423
• 89 Kanjanapan Y, Lheureux S, Oza AM. Niraparib for the treatment of ovarian cancer. Expert Opin Pharmacother 2017; 18 (06) 631-640
• 90 Vendrell JA, Ban IO, Solassol I. et al. Differential sensitivity of germline and somatic BRCA variants to PARP inhibitor in high-grade serous ovarian cancer. Int J Mol Sci 2023; 24 (18) 14181
• 91 Terraf P, Pareja F, Brown DN. et al. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing. Ann Oncol 2022; 33 (04) 426-433
• 92 Tew WP, Lacchetti C, Ellis A. et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol 2020; 38 (30) 3468-3493
• 93 Rebbeck TR, Lynch HT, Neuhausen SL. et al; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346 (21) 1616-1622
• 94 Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev 2018; 4 (04) CD002748
• 95 Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010; CD002748 (11) CD002748
• 96 Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ. et al; Hereditary Breast and Ovarian Cancer Research Group Netherlands. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 2015; 107 (05) djv033
• 97 Kotsopoulos J, Huzarski T, Gronwald J. et al; Hereditary Breast Cancer Clinical Study Group. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2016; 109 (01) djw177
• 98 Terry MB, Daly MB, Phillips KA. et al. Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk. J Natl Cancer Inst 2019; 111 (03) 331-334
• 99 NCCN. Accessed July 11, 2024 at: https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1420
• 100 Saslow D, Boetes C, Burke W. et al; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57 (02) 75-89
• 101 King MC, Wieand S, Hale K. et al; National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286 (18) 2251-2256
• 102 Tung NM, Boughey JC, Pierce LJ. et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol 2020; 38 (18) 2080-2106
• 103 Pesce C, Liederbach E, Wang C, Lapin B, Winchester DJ, Yao K. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol 2014; 21 (10) 3231-3239
• 104 Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing use of contralateral prophylactic mastectomy despite no improvement inlong term survival for invasive breast cancer. Ann Surg 2017; 265 (03) 581-589
• 105 Son KA, Lee DY, Choi D. Association of BRCA mutations and anti-müllerian hormone level in young breast cancer patients. Front Endocrinol (Lausanne) 2019; 10: 235
• 106 Rădoi VE, Țurcan M, Maioru OV. et al. Homologous recombination deficiency score determined by genomic instability in a Romanian cohort. Diagnostics (Basel) 2023; 13 (11) 1896
• 107 Robson ME, Tung N, Conte P. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30 (04) 558-566
• 108 Litton JK, Hurvitz SA, Mina LA. et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 2020; 31 (11) 1526-1535
• 109 von Minckwitz G, Schneeweiss A, Loibl S. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15 (07) 747-756
• 110 Sikov WM, Berry DA, Perou CM. et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33 (01) 13-21
• 111 Tutt ANJ, Garber JE, Kaufman B. et al; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021; 384 (25) 2394-2405
• 112 Aschenbrenner DS. New adjuvant treatment for high-risk early breast cancer. Am J Nurs 2022; 122 (07) 26
• 113 DiSilvestro P, Banerjee S, Colombo N. et al; SOLO1 Investigators. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol 2023; 41 (03) 609-617
• 114 Pujade-Lauraine E, Ledermann JA, Selle F. et al; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18 (09) 1274-1284
• 115 Fabbro M, Moore KN, Dørum A. et al. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecol Oncol 2019; 152 (03) 560-567
• 116 Oza AM, Tinker AV, Oaknin A. et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol 2017; 147 (02) 267-275
• 117 Moore K, Colombo N, Scambia G. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018; 379 (26) 2495-2505
• 118 Valarmathi MT, A A, Deo SS, Shukla NK, Das SN. BRCA1 germline mutations in Indian familial breast cancer. Hum Mutat 2003; 21 (01) 98-99
• 119 Saxena S, Chakraborty A, Kaushal M. et al. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Med Genet 2006; 7: 75
• 120 Syamala V, Sreeja L, Syamala VS. et al. Novel germline mutations in BRCA2 gene among 96 hereditary breast and breast-ovarian cancer families from Kerala, South India. J Cancer Res Clin Oncol 2007; 133 (11) 867-874
• 121 Soumittra N, Meenakumari B, Parija T. et al. Molecular genetics analysis of hereditary breast and ovarian cancer patients in India. Hered Cancer Clin Pract 2009; 7 (01) 13